|
1
|
Kleeff J, Michalski C, Friess H and
Büchler MW: Pancreatic cancer: From bench to 5-year survival.
Pancreas. 33:111–118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ueno H, Kiyosawa K and Kaniwa N:
Pharmacogenomics of gemcitabine: Can genetic studies lead to
tailor-made therapy? Br J Cancer. 97:145–151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Von Hoff DD, Goldstein D and Renschler MF:
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N
Engl J Med. 370:479–480. 2014.PubMed/NCBI
|
|
9
|
Suker M, Beumer BR, Sadot E, Marthey L,
Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ,
et al: FOLFIRINOX for locally advanced pancreatic cancer: A
systematic review and patient-level meta-analysis. Lancet Oncol.
17:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gherardi E, Birchmeier W, Birchmeier C and
Vande Woude G: Targeting MET in cancer: Rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di Renzo MF, Poulsom R, Olivero M,
Comoglio PM and Lemoine NR: Expression of the Met/hepatocyte growth
factor receptor in human pancreatic cancer. Cancer Res.
55:1129–1138. 1995.PubMed/NCBI
|
|
12
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gherardi E and Stoker M: Hepatocyte growth
factor - scatter factor: Mitogen, motogen, and met. Cancer Cells.
3:227–232. 1991.PubMed/NCBI
|
|
16
|
Ridley AJ, Comoglio PM and Hall A:
Regulation of scatter factor/hepatocyte growth factor responses by
Ras, Rac, and Rho in MDCK cells. Mol Cell Biol. 15:1110–1122. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wells CM, Ahmed T, Masters JR and Jones
GE: Rho family GTPases are activated during HGF-stimulated prostate
cancer-cell scattering. Cell Motil Cytoskeleton. 62:180–194. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zou HY, Li Q, Lee JH, Arango ME, McDonnell
SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, et al: An
orally available small-molecule inhibitor of c-Met, PF-2341066,
exhibits cytoreductive antitumor efficacy through antiproliferative
and antiangiogenic mechanisms. Cancer Res. 67:4408–4417. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Christensen JG, Zou HY, Arango ME, Li Q,
Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B and Los
G: Cytoreductive antitumor activity of PF-2341066, a novel
inhibitor of anaplastic lymphoma kinase and c-Met, in experimental
models of anaplastic large-cell lymphoma. Mol Cancer Ther.
6:3314–3322. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamazaki S, Skaptason J, Romero D, Lee JH,
Zou HY, Christensen JG, Koup JR, Smith BJ and Koudriakova T:
Pharmacokinetic-pharmacodynamic modeling of biomarker response and
tumor growth inhibition to an orally available cMet kinase
inhibitor in human tumor xenograft mouse models. Drug Metab Dispos.
36:1267–1274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Timofeevski SL, McTigue MA, Ryan K, Cui J,
Zou HY, Zhu JX, Chau F, Alton G, Karlicek S, Christensen JG, et al:
Enzymatic characterization of c-Met receptor tyrosine kinase
oncogenic mutants and kinetic studies with aminopyridine and
triazolopyrazine inhibitors. Biochemistry. 48:5339–5349. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sennino B, Ishiguro-Oonuma T, Wei Y,
Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman
HA, Christensen JG, et al: Suppression of tumor invasion and
metastasis by concurrent inhibition of c-Met and VEGF signaling in
pancreatic neuroendocrine tumors. Cancer Discov. 2:270–287. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng X, He K, Zhang L and Yu J:
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
Mol Cancer Ther. 12:777–786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Surriga O, Rajasekhar VK, Ambrosini G,
Dogan Y, Huang R and Schwartz GK: Crizotinib, a c-Met inhibitor,
prevents metastasis in a metastatic uveal melanoma model. Mol
Cancer Ther. 12:2817–2826. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou Y, Zhao C, Gery S, Braunstein GD,
Okamoto R, Alvarez R, Miles SA, Doan NB, Said JW, Gu J, et al:
Off-target effects of c-MET inhibitors on thyroid cancer cells. Mol
Cancer Ther. 13:134–143. 2014. View Article : Google Scholar
|
|
26
|
Avan A, Caretti V, Funel N, Galvani E,
Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D,
Fuchs D, et al: Crizotinib inhibits metabolic inactivation of
gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res.
73:6745–6756. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC,
Desai R, Fu L, Gnad F, Song Q, Haverty PM, et al: PAK1 mediates
pancreatic cancer cell migration and resistance to MET inhibition.
J Pathol. 234:502–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
